Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEN 1044

Next Previous
Search
Drug Profile

GEN 1044

Alternative Names: DuoBody-CD3x5T4; GEN-1044

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 06 Nov 2021 Genmab terminates a phase-I/II trial in Solid tumours (In adults, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Denmark, USA, Spain, Israel (IV) (NCT04424641) (EudraCT2019-003998-26)
  • 15 Jul 2020 Phase-I/II clinical trials in Solid tumours (In adults, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Spain, Israel (IV) (NCT04424641) (EudraCT2019-003998-26)
  • 11 Jun 2020 Genmab plans a phase I/II trial for Solid tumors (Late stage disease, Second line therapy or greater) in the US, Denmark, Spain and Israel in June 2020 (IV) (NCT04424641)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top